secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K/A
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001213900-24-018526
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma amends convertible note with $1.00 floor price; cash payment on floor conversions
--------------------------------------------------------------------------------

- Amendment to $1M secured convertible note sets floor conversion price at $1.00 per share.
- Cash payment required if conversion price equals floor price, based on formula linked to VWAP.
- Initial shareholder meeting deadline extended one month to April 17, 2024.
- Amendment adopted to comply with Nasdaq listing requirements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024018526/0001213900-24-018526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024018526/ea0200876-8ka1_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-018526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer